From: Molecular subtyping and improved treatment of neurodevelopmental disease
Gene | ASDb | ID/DDc | EPd | SZe | Total cases | Control countsf | p value | OR (95Â % CI) | Pathwayg |
---|---|---|---|---|---|---|---|---|---|
SYNGAP1 a | 7 | 9 | 0 | 0 | 16 | 1 | 1.45E-12 | 88.0 (13.7–3613.0) | S |
SCN2A a | 6 | 7 | 0 | 1 | 14 | 1 | 1.34E-11 | 86.7 (13.2–3587.4) | S |
ARID1B a | 5 | 11 | 0 | 0 | 16 | 5 | 9.29E-10 | 17.6 (6.2–61.5) | C, T, W |
ANKRD11 a | 2 | 8 | 0 | 0 | 10 | 1 | 2.63E-08 | 61.9 (8.8–2644.0) | D |
CHD8 a | 12 | 0 | 0 | 1 | 13 | 4 | 3.52E-08 | 17.9 (5.5–75.2) | C, T, W |
ADNP a | 5 | 4 | 0 | 0 | 9 | 2 | 1.99E-06 | 24.7 (5.1–234.2) | T |
DYRK1A a | 5 | 3 | 0 | 0 | 8 | 1 | 2.46E-06 | 44.0 (5.9–1929.7) | K, D |
CTNNB1 a | 1 | 6 | 0 | 0 | 7 | 1 | 1.42E-05 | 38.5 (4.9–1716.8) | T, W |
CHD2 a | 5 | 2 | 1 | 0 | 8 | 3 | 3.36E-05 | 14.7 (3.5–85.7) | C, T |
STXBP1 | 0 | 5 | 1 | 0 | 6 | 1 | 8.12E-05 | 32.9 (4.0–1503.0) | S |
POGZ | 3 | 2 | 0 | 1 | 6 | 2 | 1.58E-04 | 18.5 (3.3–187.6) | R |
MED13L | 2 | 4 | 0 | 0 | 6 | 2 | 2.82E-04 | 16.5 (2.9–166.8) | T, W |
TRIP12 | 2 | 2 | 0 | 0 | 4 | 0 | 5.63E-04 | ∞ (3.6–∞) | U |
KMT2A | 2 | 4 | 0 | 0 | 6 | 4 | 9.24E-04 | 9.3 (2.2–44.7) | C |
EP300 | 1 | 4 | 0 | 0 | 5 | 3 | 2.03E-03 | 10.3 (2.0–66.5) | C, T, W |
GRIN2B | 3 | 1 | 0 | 0 | 4 | 1 | 2.47E-03 | 22.0 (2.2-1075.1) | S |
DDX3X a | 1 | 2 | 0 | 0 | 3 | 0 | 2.70E-03 | ∞ (2.6–∞) | T, W |
SUV420H1 | 3 | 0 | 0 | 0 | 3 | 0 | 2.70E-03 | ∞ (2.6–∞) | C, T |
WDR45 | 0 | 2 | 1 | 0 | 3 | 0 | 2.70E-03 | ∞ (2.6–∞) | A |
CHAMP1 a | 0 | 3 | 0 | 0 | 3 | 0 | 3.66E-03 | ∞ (2.3–∞) | R |
SCN1A a | 0 | 0 | 4 | 0 | 4 | 2 | 6.50E-03 | 11.0 (1.6–121.5) | S |
WAC a | 2 | 2 | 0 | 0 | 4 | 2 | 6.50E-03 | 11.0 (1.6–121.5) | C, T |
AHDC1 a | 1 | 2 | 0 | 0 | 3 | 1 | 9.68E-03 | 18.5 (1.5–967.5) | Db |
SATB2 | 0 | 3 | 0 | 0 | 3 | 1 | 9.68E-03 | 18.5 (1.5–967.5) | C, T |